Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study

Cristóbal Morales, Juan Francisco Merino-Torres, Paloma Moreno-Moreno, María Lainez, Iñigo Tejado, Alfredo Yoldi, Sonsoles Gutiérrez Medina, Alfonso Soto, Manuel A Botana, Virginia Bellido, Irene Caballero

Abstract

Background: This study aims to evaluate dapagliflozin in patients with type 2 diabetes (T2D) in clinical practice in Spain.

Methods: This is a retrospective study including adults with T2D under stable antidiabetic therapy, with either dapagliflozin or sitagliptin ≥6 months, before inclusion. Data about the effectiveness and safety of dapagliflozin are presented.

Results: A total of 594 patients (61.8±9.9 years, 21.7% cardiovascular disease) were included. After 6 months, HbA1c, weight, blood pressure, urine albumin-to-creatinine ratio and uric acid significantly decreased (1.63%, 2.88 kg, 4.82/2.70 mmHg, −17.38 mg/g and −0.30 mg/dL, respectively), whereas glomerular filtration rate and haematocrit significantly increased (3.72 mL/min/1.73 m2 and 1.8%, respectively). No cases of hypoglycaemia, diabetic ketoacidosis, Fournier gangrene, fractures or amputations were reported.

Conclusion: Thus, dapagliflozin provides a comprehensive cardiometabolic protection in patients with T2D.

Article Details

Article Type

Original Research

DOI

10.7573/dic.2021-11-5

Categories

Publication Dates

Accepted: ; Published: .

Citation

Morales C, Merino-Torres JF, Moreno-Moreno P, Lainez M, Tejado I, Yoldi A, Gutiérrez Medina S, Soto A, Botana MA, Bellido V, Caballero I. Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study. Drugs Context. 2022;11:2021-11-5. https://doi.org/10.7573/dic.2021-11-5

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.